The Roman empire : B. C. 29-A. D. 476 /

Includes index.

The student's Roman empire. A history of the Roman empire from its foundation to the death of Marcus Aurelius [27 B.C.-180 A.D.]

Mode of access: Internet.

Selections from the sources of English history : being a supplement to text-books of English history B.C. 55-A.D. 1832 /

Includes biographical references and index.

Outline of English history, B.C. 55-A.D. 1886.

Mode of access: Internet.

Illustrated English history, B.C. 55-A.D.[1886]

Mode of access: Internet.

Alsace and Lorraine from Cæsar to Kaiser, 58 B.C.-1871 A.D.,

Appendices: I. The treaties; diplomatic articles by which the political status of Alsace and Lorraine ... has been affected (p. 201-205); II. Main sources used for the narrative (p. 206-208)

Biographical dictionary of medallists; coin, gem, and seal-engravers, mint-masters, &c., ancient and modern, with references to their works B.C. 500-A.D. 1900;

Vol. 1 of NUMRF copy is 1904 ed.

Observations of comets : from 611 B.C. to A.D.1640 : extracted from the Chinese annals /

Reprint. Originally published: London : s.n., 1871.

General history of Rome from the foundation of the city to the fall of Augustulus, B.C. 753-A.D. 476.

Mode of access: Internet.

Arminivs, cheruscorum, dux ac decus liberator germaniae.

Mode of access: Internet.

Konon, Text und Quellenuntersuchung /

Mode of access: Internet.

A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/ cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer : a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)

Background: Phase III studies suggest that non-small-cell lung cancer (NSCLC) patients treated with cisplatin-docetaxel may have higher response rates and better survival compared with other platinum-based regimens. We report the final results of a randomised phase III study of docetaxel and carboplatin versus MIC or MVP in patients with advanced NSCLC. Patients and methods: Patients with biopsy proven stage III-IV NSCLC not suitable for curative surgery or radiotherapy were randomised to receive four cycles of either DCb (docetaxel 75 mg/m 2, carboplatin AUC 6), or MIC/MVP (mitomycin 6 mg/m 2, ifosfamide 3 g/m 2 and cisplatin 50 mg/m 2 or mitomycin 6 mg/ m 2, vinblastine 6 mg/m 2 and cisplatin 50 mg/m 2, respectively), 3 weekly. The primary end point was survival, secondary end points included response rates, toxicity and quality of life. Results: The median follow-up was 17.4 months. Overall response rate was 32% for both arms (partial response = 31%, complete response = 1%); 32% of MIC/MVP and 26% of DCb patients had stable disease. One-year survival was 39% and 35% for DCb and MIC/MVP, respectively. Two-year survival was 13% with both arms. Grade 3/4 neutropenia (74% versus 43%, P < 0.005), infection (18% versus 9%, P = 0.01) and mucositis (5% versus 1%, P = 0.02) were more common with DCb than MIC/MVP. The MIC/MVP arm had significant worsening in overall EORTC score and global health status whereas the DCb arm showed no significant change. Conclusions: The combination of DCb had similar efficacy to MIC/MVP but quality of life was better maintained. © 2006 European Society for Medical Oncology.

Annual report 1992 - North Pacific Marine Science Organization (PICES). First meeting, Victoria, B.C., Canada, October 12-17, 1992

Document has 52 pages.

Forty years in the Turkish Empire, or, Memoirs of Rev. William Goodell : late missionary of the A.B.C.F.M. at Constaninople /

Mode of access: Internet.